COVID-19 疫情对炎症性风湿病患者疾病病程的影响:瑞士临床质量管理队列结果
该研究基于瑞士临床质量管理队列,比较 2020 年 1 至 6 月疫情前、中、后三个各 2 个月时段,666 例中轴型脊柱关节炎(axSpA)、类风湿关节炎(RA)和银屑病关节炎(PsA)患者的患者报告疾病活动度。结果显示面对面就诊下降 52%、远程评估增加 129%,axSpA 用药不依从比例在疫情期间轻微上升且差异有统计学意义(19.9% vs 13.2%,p=0.003),疾病 flare 比例保持稳定(<15%),各病患者报告活动度均值无增加。结论认为短期中断面对面医患互动对 axSpA、RA 和 PsA 的疾病病程无重大不良影响。
要点
- 疫情期间面对面就诊下降 52%,远程评估增加 129%。
- axSpA 用药不依从比例升至 19.9%,高于疫情前 13.2%(p=0.003)。
- axSpA、RA 和 PsA 疾病 flare 比例稳定在 <15%,患者报告活动度均值未升高。
核心结论
- 短期中断面对面医患互动对 axSpA、RA 和 PsA 的疾病病程无重大不良影响,依据为患者报告结局。
研究设计与样本
- 基于瑞士临床质量管理队列,比较 2020 年 1 至 6 月疫情前、中、后三个各 2 个月时段的患者报告疾病活动度。
- 纳入 666 例 axSpA、RA 和 PsA 患者,疾病活动度通过面对面就诊和/或智能手机应用评估。
主要发现
- 面对面就诊次数下降 52%,远程评估次数增加 129%。
- axSpA 用药不依从比例在疫情期间轻微上升,达 19.9%,疫情前为 13.2%(p=0.003)。
- 疾病 flare 比例保持稳定(<15%)。
- axSpA 的 Bath 强直性脊柱炎疾病活动指数、RA 的疾病活动指数-5 和 PsA 的患者总体评估均值均未增加。
临床怎么用
- 在疫情等突发情况下短期减少面对面就诊、增加远程评估,可能不会导致 axSpA、RA 和 PsA 患者报告疾病活动度明显恶化。
- 应关注 axSpA 患者用药不依从比例在疫情期间的轻微上升。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To investigate whether the transient reduction in rheumatology services imposed by virus containment measures during the COVID-19 pandemic was associated with disease worsening in axial spondyloarthritis (axSpA), rheumatoid arthritis (RA) or psoriatic arthritis (PsA). METHODS: Patient-reported disease activity assessed during face-to-face visits and/or via a smartphone application were compared between three periods of each 2 months duration (before, during and after the COVID-19-wave) from January to June 2020 in 666 patients with axSpA, RA and PsA in the Swiss Clinical Quality Management cohort. RESULTS: The number of consultations dropped by 52%, whereas the number of remote assessments increased by 129%. The proportion of patients with drug non-compliance slightly increased during the pandemic, the difference reaching statistical significance in axSpA (19.9% vs 13.2% before the pandemic, p=0.003). The proportion of patients with disease flares remained stable (<15%). There was no increase in mean values of the Bath Ankylosing Disease Activity Index, the Rheumatoid Arthritis Disease Activity Index-5 and the Patient Global Assessment in patients with axSpA, RA and PsA, respectively. CONCLUSION: A short interruption of in-person patient-rheumatologist interactions had no major detrimental impact on the disease course of axSpA, RA and PsA as assessed by patient-reported outcomes.
引用
- Ciurea A, Papagiannoulis E, Bürki K, et al. Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort. Ann Rheum Dis. 2020. PMID: 32963052. doi:10.1136/annrheumdis-2020-218705
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。